S&P Futures
4,109.25 -38.50 (-0.93%) Dow Futures
33,708.00 -254.00 (-0.75%) Nasdaq Futures
12,478.00 -146.00 (-1.16%) Russell 2000 Futures
1,973.70 -19.80 (-0.99%) Crude Oil
73.64 +0.25 (+0.34%) Gold
1,884.90 +8.30 (+0.44%)
CytomX Therapeutics, Inc. (CTMX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 2.5900 |
| Open | 2.6000 |
| Bid | 2.6400 x 2200 |
| Ask | 2.7400 x 2900 |
| Day's Range | 2.6000 - 2.7100 |
| 52 Week Range | 1.1700 - 4.7300 |
| Volume | |
| Avg. Volume | 3,259,680 |
| Market Cap | 175.124M |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7130 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.41 |
- GlobeNewswire
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights for select programs- SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas. Th
- GlobeNewswire
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 19, 2023 at 2:30 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of Cytom
- Simply Wall St.
An Intrinsic Calculation For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Suggests It's 38% Undervalued
Does the January share price for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) reflect what it's really worth? Today, we...
